

LA JOLLA PHARMACEUTICAL CO

Form 8-K

August 04, 2003

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): August 4, 2003

**LA JOLLA PHARMACEUTICAL COMPANY**

---

(Exact Name of Registrant as Specified in Charter)

Delaware

0-24274

33-0361285

---

(State or Other Jurisdiction of  
Incorporation)

---

(Commission File Number)

---

(IRS Employer  
Identification No.)

6455 Nancy Ridge Drive  
San Diego, California 92121  
(Address of Principal Executive Offices, Including Zip Code)

Registrant's telephone number, including area code: (858) 452-6600

---

---

---

**TABLE OF CONTENTS**

Item 12. Results of Operations and Financial Condition.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 12. Results of Operations and Financial Condition.**

In a press release on August 4, 2003, La Jolla Pharmaceutical Company (the Company ) announced and commented on its financial results for the second quarter 2003. A copy of the Company's press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The press release is being furnished to the Securities and Exchange Commission under Item 12. Results of Operations and Financial Condition.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 4, 2003

**LA JOLLA PHARMACEUTICAL COMPANY**

By: /s/ Steven B. Engle

---

Steven B. Engle  
Chairman of the Board and  
Chief Executive Officer

**Table of Contents**

**EXHIBIT INDEX**

<b><u>Exhibit Number</u></b>	<b><u>Description of Exhibit</u></b>
99.1	Press Release